Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern

Severe Acute Respiratory Syndrome Coronavirus 2 is the causal pathogen of coronavirus disease 2019 (COVID-19). The emergence of new variants with different mutational patterns has limited the therapeutic options available and complicated the development of effective neutralizing antibodies targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Valdovino-Navarro, Blanca J., Dueñas, Salvador, Flores-Acosta, G. Isaí, Gasperin-Bulbarela, Jahaziel, Bernaldez-Sarabia, Johanna, Cabanillas-Bernal, Olivia, Cervantes-Luevano, Karla E., Licea-Navarro, Alexei F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603574/
https://www.ncbi.nlm.nih.gov/pubmed/36293124
http://dx.doi.org/10.3390/ijms232012267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603574/
https://www.ncbi.nlm.nih.gov/pubmed/36293124
http://dx.doi.org/10.3390/ijms232012267

Ejemplares similares